文献速递前列腺癌

新型前列腺内磁共振引导植入多药洗脱微装置用于原位系统性治疗药物测试:中危和高危前列腺癌的概念验证

Novel Intraprostatic Magnetic Resonance-Guided Implantation of Multidrug-Eluting Microdevice for Testing of Systemic Therapy Agents In Situ: Proof of Concept in Intermediate-Risk and High-Risk Prostate Cancer.
PubMed 文献 · J Urol · 2024-09-30

本研究评估经皮磁共振引导放置可植入微装置(IMD)以原位评估多种药物对中危和高危局限性前列腺癌瘤内反应的安全性和可行性。共入组14例患者,植入53个IMD(平均每例3.8个),49个(92%)成功回收,无严重不良事件。组织病理学检查显示药物反应存在患者内和患者间差异。

要点

  • 多药IMD可安全经皮植入MRI可见病灶,在根治性前列腺切除术前评估多种药物的原位瘤内反应。
  • 14例患者中7例(50%)中危、7例(50%)高危,共植入53个IMD,平均每例3.8个,49个(92%)成功回收。
  • 所有患者IMD放置2天后行机器人辅助根治性前列腺切除加双侧盆腔淋巴结清扫,无并发症,无严重不良事件。

核心结论

  • 多药IMD可安全经皮植入MRI可见病灶,在根治性前列腺切除术前同时评估肿瘤在正常基质环境内对多种药物的特异性局部反应,以指导靶向系统性治疗。

研究设计与样本

  • 前瞻性概念验证研究,入组中危或高危局限性前列腺癌且MRI可见病灶的男性患者,共14例。
  • IMD直径750微米、长5毫米,含20个储库,装载候选药物及药物组合包括第二代雄激素抑制剂、PARP抑制剂、PD-1抑制剂和常规化疗。
  • 经会阴途径将最多4个IMD植入MRI可见肿瘤,计划根治性前列腺切除术前2天放置。

主要发现

  • 14例患者中7例(50%)为中危、7例(50%)为高危局限性前列腺癌。
  • 共植入53个IMD(平均每例3.8个),49个(92%)成功回收。
  • 所有患者IMD放置2天后行机器人辅助根治性前列腺切除加双侧盆腔淋巴结清扫,无并发症。
  • 无严重不良事件。
  • IMD邻近组织病理检查显示药物反应存在患者内和患者间差异。

局限性

  • 局限性包括样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to assess safety and feasibility of percutaneous magnetic resonance-guided placement of an implantable microdevice (IMD) to evaluate in situ intratumor response to multiple pharmacologic agents in men with intermediate-risk and high-risk localized prostate cancer. MATERIALS AND METHODS: Biocompatible IMDs measuring 750 µm in diameter and 5 mm in length were prepared with 20 reservoirs containing candidate drug and drug combinations including second-generation androgen inhibitors, PARP inhibitors, PD-1 inhibitors, and conventional chemotherapy. Men with intermediate-risk or high-risk localized prostate cancer and MRI-visible lesions were enrolled. Up to 4 IMDs were placed using a transperineal approach into MRI-visible tumors 2 days before planned radical prostatectomy. After radical prostatectomy, the IMDs and a small segment of surrounding tumor tissue were removed and sectioned, stained, and analyzed for tissue drug response by a variety of pharmacodynamic markers. RESULTS: Fourteen patients were enrolled: 7 (50%) with intermediate-risk and 7 (50%) with high-risk localized prostate cancer. A total of 53 IMDs were implanted (mean 3.8 per patient), and 49 IMDs (92%) were successfully retrieved. All men underwent uncomplicated robotic-assisted radical prostatectomy and bilateral pelvic lymph node dissection 2 days after IMD placement. There were no severe adverse events. Pathological examination of the tissues adjacent to the IMDs demonstrated differential drug response within patients and between patients. Limitations include small sample size. CONCLUSIONS: A multidrug IMD can be safely placed percutaneously into MRI-visible lesions before radical prostatectomy, enabling assessment of tumor-specific local response to multiple agents simultaneously within the tumor's normal stromal environment to guide targeted systemic therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04399876.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stone BV, Dominas CA, Bhagavatula SK, et al. Novel Intraprostatic Magnetic Resonance-Guided Implantation of Multidrug-Eluting Microdevice for Testing of Systemic Therapy Agents In Situ: Proof of Concept in Intermediate-Risk and High-Risk Prostate Cancer. J Urol. 2024. PMID: 39348711. doi:10.1097/JU.0000000000004269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。